Diabetes Metab J.  2020 Apr;44(2):245-247. 10.4093/dmj.2020.0073.

Biomarker Score in Risk Prediction: Beyond Scientific Evidence and Statistical Performance

• Bang H

• KMID: 2502405
• DOI: http://doi.org/10.4093/dmj.2020.0073

Reference

1. Shmueli G. To explain or to predict? Statist Sci. 2010; 25:289–310.

2. Breiman L. Statistical modeling: the two cultures. Statist Sci. 2001; 16:199–231.

3. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363:157–163. PMID: 14726171.

4. Matsushita K, Tang O, Selvin E. Addressing challenges and implications of national surveillance for racial/ethnic disparities in diabetes. JAMA. 2019; 322:2387–2388. PMID: 31860028.

5. Haddix AC, Teutsch SM, Corso PS. Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford: Oxford University Press;1996.

6. Poltavskiy E, Kim DJ, Bang H. Comparison of screening scores for diabetes and prediabetes. Diabetes Res Clin Pract. 2016; 118:146–153. PMID: 27371780.

7. Ha KH, Lee YH, Song SO, Lee JW, Kim DW, Cho KH, Kim DJ. Development and validation of the Korean diabetes risk score: a 10-year national cohort study. Diabetes Metab J. 2018; 42:402–414. PMID: 30113144.

8. Lee YH, Bang H, Kim HC, Kim HM, Park SW, Kim DJ. A simple screening score for diabetes for the Korean population: development, validation, and comparison with other scores. Diabetes Care. 2012; 35:1723–1730. PMID: 22688547.

9. Wyatt JC, Altman DG. Prognostic models: clinically useful or quickly forgotten? BMJ. 1995; 311:1539.

10. Liao L, Mark DB. Clinical prediction models: are we building better mousetraps? J Am Coll Cardiol. 2003; 42:851–853. PMID: 12957431.

11. Adibi A, Sadatsafavi M, Ioannidis JPA. Validation and utility testing of clinical prediction models: time to change the approach. JAMA. 2020; 3. 05. DOI: 10.1001/jama.2020.1230. [Epub].

12. Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, Lassale CM, Siontis GC, Chiocchia V, Roberts C, Schlussel MM, Gerry S, Black JA, Heus P, van der Schouw YT, Peelen LM, Moons KG. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016; 353:i2416. PMID: 27184143.

13. Wang Y, Koh WP, Sim X, Yuan JM, Pan A. Multiple biomarkers improved prediction for the risk of type 2 diabetes mellitus in Singapore Chinese men and women. Diabetes Metab. 2020; 44:295–306.

14. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology. 2014; 25:114–121. PMID: 24240655.

15. Chow SC. Chapter 95, Cost-effectiveness analysis. Encyclopedia of biopharmaceutical statistics. 3rd ed. Boca Raton: CRC Press;2010.

16. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009; 101:1044–1048. PMID: 19564563.

17. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014; 32:1277–1280. PMID: 24638016.

18. Lee YH, Bang H, Kim DJ. How to establish clinical prediction models. Endocrinol Metab (Seoul). 2016; 31:38–44. PMID: 26996421.

19. Goldstein DG, Gigerenzer G. Fast and frugal forecasting. Int J Forecast. 2009; 25:760–772.

20. Raper S. Leo Breiman's “two cultures”. Significance. 2020; 17:34–37.